![MIS Contacts Sean Robson, MBA Business Development Director [email_address] +44 1344 412333 Kevin Farberow, MBA Vice-President Global Sales and Marketing [email_address] +1 609-268-4495](https://image.slidesharecdn.com/miscredentials-june2009-090615045751-phpapp02/85/Mis-Credentials-June-2009-11-320.jpg)
Mis Credentials June 2009
- 1. Medical Intelligence Solutions June 2009 Sean Robson MBA Business Development Director
- 2. Quick Guide Why MIS Online service links- examples of use Early access to clinical data Includes relevant data from other therapy areas which may otherwise be missed Unique and flexible searchability An archive of data for trend analysis
- 3. Why MIS- What Sets Us Apart ? Unparalleled database of meetings-based clinical intelligence Real time content ingestion Flexible searching and delivery of customised analysis and customised alerts ‘ Early warning’ of competitor threats Use data to challenge business assumptions
- 4. Value of Clinical Meetings – Timely & Comprehensive but Diverse Formats The most timely clinical data available Only 45% of all meeting abstracts are ever published in peer-reviewed journals Only 27% are published within the first two years!* Normalised format- Abstracts otherwise appear in multiple formats, eg Abstract books CD-ROMs/ DVD’s PDF’s Online, etc Before it’s a press release… Before it’s published in a journal… Before it’s a promotional claim… Before it’s in an ad… IT APPEARS AT A MEETING! * BMC Medical Research Methodology 2003, 3:12
- 5. MIS- Unique Database – Unique Subscription Options Unrivaled Normalised Content 3.3 Million Presentation Abstracts Normalised and Searchable Abstracts tagged by TA, meeting, author and affiliation etc 17 Million Publication Records 700,000+ Abstracts Annually c12-15 abstracts per week Custom alerts inform of new relevant data 5300+ meetings monitored across the world annually Synonym/thesaurus dictionaries applied Benchmarked against Published literature Timely, relevant, customized services
- 6. Sample abstract showing title, authors, affiliation and meeting Bendamustine appears to be less cost-effective than other therapeutic regimens for the treatment of CLL
- 7. Meetings Tracked by Therapeutic Areas
- 8. Identification of unmet medical needs, new treatment trends and clinical opportunities The current and future competitive landscape for a therapeutic area or class of drugs Drug targets that are currently being analyzed for a particular disease indication What molecules similar to yours are being studied? Do those molecules have the same, better or less safety and efficacy that your drug? Which competitors are actively developing new therapies in those therapeutic areas and what are their chances of success? What is the quantity and quality of your competitors' studies? Which indications should your drug be trialed for? Common Questions Answered by KDP Knowledge Discovery Platform (KDP)
- 9. Medical Intelligence Solutions: Database Synergies MIS: Continuum of Services
- 10. Medical Intelligence Solutions The importance of early access to medical meeting data The searchability to make this data actionable by yourselves The relevance to challenge assumptions
- 11. MIS Contacts Sean Robson, MBA Business Development Director [email_address] +44 1344 412333 Kevin Farberow, MBA Vice-President Global Sales and Marketing [email_address] +1 609-268-4495